The Market

Overactive bladder and bladder cancer combined, mirror more than $2 Billion annual market opportunity in the U.S..

The Product

Vensica is developing a platform for improved drug delivery to the urinary bladder.

The Team

Read about the people behind the technology. The respected leaders of therapeutic ultrasound care and drug delivery.

What Professionals Say

Vensica could change the way we manage OAB

Prof. Alan Wein (hon) Founder Professor and Chief of urology at the University of Pennsylvania. A pioneer in the overactive bladder space

Vensica can be a home run and a victory

Prof. Roger Dmochowski A key opinion leader urologist from Vanderbilt Uni. Medical Center, Nashville, TN. Allergan’s PI in clinical trials for Botulinum Toxin A for OAB

CONTACT US





We would love to hear from you. Please leave us a note and we will make sure to get back as soon as possible